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AJOG at a glance 69 
A. Standardizing definitions for individual core outcomes presents an opportunity to develop 70 
additional harmony in future pre-eclampsia research and ensure secondary research can 71 
be undertaken  prospectively, efficiently, and harmoniously.  72 
B. Using formal consensus development methods healthcare professionals and 73 
researchers have developed standardized definitions for the pre-eclampsia core 74 
outcome set for use within future randomized controlled trials and systematic reviews. 75 
C. Consensus on measurements for the pre-eclampsia core outcome set will help to ensure 76 
consistency across future randomized controlled trials and systematic reviews, making 77 
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While a core outcome set for pre-eclampsia has been established, this is necessary but not 113 
sufficient. Different definitions exist for individual core outcomes. Such variation makes it 114 
difficult to synthesize the results of individual randomized controlled trials within secondary 115 
research. Standardizing definitions for individual core outcomes presents an opportunity to 116 
develop additional harmony across future pre-eclampsia research 117 
Objectives 118 
To develop consensus definitions for the core outcome set for pre-eclampsia. 119 
Study design 120 
Potential definitions for outcomes previously chosen in the core outcome set development 121 
process were identified across four formal definition development initiatives, nine national 122 
and international guidelines, 12 Cochrane systematic reviews, and 79 randomized controlled 123 
trials, and entered into a consensus development conference. These definitions were 124 
entered into a consensus development conference, including ten healthcare professionals 125 
and three researchers, plus six participants with experience of conducting research in low- 126 
and middle-income countries. A definition hierarchy structured the discussion for each core 127 
outcome. A prior consensus definition was unanimous agreement. 128 
Results 129 
Eighty-six definitions were entered into the consensus development conference. Consensus 130 
was reached for all core outcomes including 14 maternal, four fetal, and four neonatal. When 131 
considering stroke, pulmonary edema, and neonatal seizures, separate consensus 132 
definitions were developed for high-income countries and low- and middle-income countries. 133 




Consensus on measurements for the pre-eclampsia core outcome set will help to ensure 135 
consistency across future randomized controlled trials, systematic reviews, and clinical 136 
practice guidelines. Such standardization should make research evidence more accessible 137 
and facilitate the translation of research into clinical practice. 138 
Clinical trial registration 139 
Core Outcome Measures in Effectiveness Trials Initiative, www.comet-140 































Randomized controlled trials evaluating potential treatments for pre-eclampsia have reported 169 
many different outcomes.1-3 Such variation contributes to challenges in comparing, 170 
contrasting, and combining individual pre-eclampsia trials, limiting the usefulness of research 171 
to inform clinical practice. The development, dissemination, and implementation of a core 172 
outcome set for pre-eclampsia should address the variation in outcome selection, collection, 173 
and reporting in randomized trials and ensure the future evidence base is meaningful to 174 
diverse stakeholders, including women with pre-eclampsia.4 175 
 176 
While a core outcome set for pre-eclampsia has been established, this is necessary but not 177 
sufficient. Different definitions exist for individual core outcomes. For example, stillbirth has 178 
been defined using six different combinations of gestational ages, birth weights, and crown-179 
heel heights (Table 1).5 Such variation makes it difficult to synthesize the results of individual 180 
randomized controlled trials within secondary research, including individual pair-wise meta-181 
analysis, patient data meta-analysis, and network meta-analysis.6 Standardizing definitions 182 
for individual core outcomes presents an opportunity to develop additional harmony in future 183 
pre-eclampsia research and ensure secondary research can be undertaking prospectively, 184 
efficiently, and harmoniously. 185 
 186 
No guidelines have established recommendations regarding the selection of definitions for 187 
individual core outcomes.7 Outside the context of core outcome set development, the World 188 
Health Organization’s Working Group on Maternal Mortality and Morbidity Classifications has 189 
standardized and validated a range of definitions.8 An international working group of experts 190 
undertook a systematic review of maternal mortality/morbidity definitions and assessed their 191 
feasibility in high-, middle-, and low-income countries. The systematic review supported the 192 
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development of standardized definitions for mortality and specific morbidities, including 193 
eclampsia, renal failure, and mechanical ventilation.9 Standardized definitions were 194 
demonstrated to be feasible in a high-income country (Canada) and a middle-income 195 
country (Brazil).10,11 Other initiatives, including the World Health Organization’s ICD-11, 196 
Brighton Collaboration, and International Network of Obstetric Surveillance Systems, have 197 
standardized, but not validated, several maternal, fetal, and neonatal definitions.5,12-15 198 
 199 
In this study, we used robust consensus development methods to generate agreement on 200 
definitions for the core outcome set for pre-eclampsia. 201 
 202 
Materials and methods 203 
An international steering group, including healthcare professionals, researchers, and patient 204 
representatives, was formed to guide the development of this core outcome measurement 205 
set. Members of the steering group represented various disciplines, geographical areas, and 206 
expertise. 207 
 208 
Sources of potential definitions for individual core outcomes 209 
Potential definitions were sourced from formal definition development initiatives, national and 210 
international guidelines, Cochrane systematic reviews, and randomized controlled trials 211 
(Figure 1). Specific methods have been published elsewhere, briefly: 212 
 A systematic review was undertaken searching the Core Outcome Measures in 213 
Effectiveness Trials (COMET) initiative register to identify definition development 214 
initiatives relevant to pregnancy and childbirth research from inception to January 215 
2017.16  216 
 A recently published systematic review of national and international pre-eclampsia 217 
guidelines was used to source definitions used within these guidelines.17  218 
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 Cochrane systematic reviews evaluating potential treatments for pre-eclampsia were 219 
identified by searching the Cochrane Database of Systematic Reviews (CDSR) from 220 
inception to August 2017, again aiming to identify standardized definitions.  221 
 Randomized controlled trials evaluating potential treatments for pre-eclampsia where 222 
outcomes may have been defined were identified by searching bibliographical 223 
databases, including the Cochrane Central Register of Controlled Trials, MEDLINE, and 224 
EMBASE, from inception to January 2016.  225 
 226 
An inventory of potential definitions was developed. Using a pilot-tested and standardized 227 
data extraction form, definitions were extracted verbatim from all sources. When a definition 228 
was not explicitly stated in a published trial report, the corresponding researcher was 229 
contacted to seek further clarification. From these different sources, 86 potential definitions 230 
were identified for the 14 maternal, four fetal, and four neonatal core outcomes that had 231 
already been identified (Table 2).18 232 
 233 
Consensus development conference. 234 
Healthcare professionals and researchers, who lived in the United Kingdom, and had 235 
participated in the development of a core outcome set for pre-eclampsia, were invited to 236 
participate in a consensus definition development conference.4 There is no robust method 237 
for calculating the required number of participants which needs to be broad enough to 238 
include relevant stakeholders but small enough for adequate discussion to ensure that 239 
consensus is possible.19 Following consultation with the study’s steering group, we aimed to 240 
recruit between ten and 15 participants, as this number has yielded sufficient results and 241 
face validity in other settings.19  242 
 243 
The consensus development method was delivered through a half day consensus 244 
development conference. The meeting was chaired by one of us who was an experienced 245 
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facilitator (RJM). Before starting the meeting, participants provided demographic details, 246 
including age, gender, and ethnic group, and made an explicit commitment to participate 247 
actively.  248 
 249 
The group discussion followed an informal format with the chairperson providing direction. 250 
Each core outcome was discussed in turn. Potential definitions were displayed within the 251 
definition hierarchy. Participants were encouraged to voice their opinions on previously used 252 
definitions, to suggest new definitions if necessary and to reformulate individual definitions to 253 
improve clarity or comprehension. The a priori definition of consensus used within this study 254 
was unanimous agreement. Although the group was encouraged to reach consensus, 255 




Eighty-six potential outcome definitions were drawn from four definition development 260 
initiatives,5,8,12,14,15,20,21 nine national and international clinical practice guidelines,22-28 12 261 
Cochrane systematic reviews,29-39 and 79 pre-eclampsia trials (Appendix S1).40-120 Thirteen 262 
participants participated in the consensus development conference (Table S1) comprising 263 
ten healthcare professionals (77%) and three researchers (23%). Six (46%) had experience 264 
or working in or conducting research in low- and middle-income countries. 265 
 266 
Maternal core outcomes 267 
Maternal mortality: Participants noted consistency across definitions in terms of a limit of 42 268 
days after delivery, pregnant termination or miscarriage, a historical limit based upon the 269 
approximate timing of first menstrual period in non-lactating women (Table 3).121 Participants 270 
discussed the possibility to extend the definition by including deaths attributable to 271 
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complications of pre-eclampsia later than 42 days, however, concerns were expressed 272 
regarding the feasibility of longer follow-up in low- and middle- income countries. 273 
 274 
Eclampsia: Participants identified inconsistencies in terminology across different definitions 275 
of eclampsia. A unanimous decision was made to define eclampsia as “the onset of 276 
convulsions in a woman with pre-eclampsia, not attributable to other causes”. Participants 277 
discussed the importance of acknowledging the various terminology used in different 278 
settings related to convulsions including fits, generalized convulsions, tonic-clonic seizure, 279 
and seizure. 280 
 281 
Stroke: Participants recognized pre-eclampsia as an important risk factor for both ischemic 282 
and hemorrhagic stroke.122 Discussion focused upon the challenges of obtaining 283 
computerized tomography or magnetic resonance imaging in low- and middle-income 284 
countries, and as such separate definitions were agreed for high-income countries and low- 285 
and middle-income countries. 286 
 287 
Cortical blindness: In the single potential definition identified, participants noted the 288 
requirement to measure visual acuity and the challenges of doing so. Such measurement is 289 
not a core competency for healthcare professionals in maternity settings, and the necessary 290 
equipment to measure visual acuity is often not readily available. Participants concluded a 291 
patient-reported symptom of visual impairment would be comparable and negate the 292 
requirement to undertake visual acuity measurement.  293 
 294 
Retinal detachment: Participants appreciated the simplicity of the World Health 295 
Organization’s definition: “a condition in which the retina peels away from its underlying layer 296 
of support tissue.”14 However, the importance of undertaking an ophthalmological 297 
examination to confirm the diagnosis was discussed and considered essential in securing a 298 
robust diagnosis. 299 




Pulmonary edema: Participants agreed the clinical signs of pulmonary edema are relatively 301 
straightforward to elicit during respiratory system auscultation. The discussion focused upon 302 
chest x-ray confirmation. Concerns were expressed regarding the availability of X-ray 303 
facilities in low- and middle-income countries. To address these concerns, participants 304 
agreed to include the requirement for directive treatment and an oxygen saturation below 305 
95% when a chest x-ray is unavailable. 306 
 307 
Acute kidney injury: Participants noted a diverse range of different definitions of acute kidney 308 
injury. A pragmatic decision was made to implement the National Institute for Health and 309 
Care Excellence standardized definition which shares a common definition with other recent 310 
national and international initiatives including Risk, Injury, Failure, Loss, End-stage (RIFLE) 311 
renal disease, Acute Kidney Injury Network, and Kidney Disease: Improving Global 312 
Outcomes.123-126 The discussion focused upon the measurement of creatinine during routine 313 
antenatal care. A baseline creatinine is not routinely measured in lower risk women and may 314 
not have been measured before pregnancy.127 Therefore, an additional criterion was added 315 
to the consensus definition: serum creatinine >150 micromol/liter in the absence of a 316 
baseline serum creatinine. 317 
 318 
Liver capsule hematoma: Participants unanimously recommended the definition previously 319 
reported in randomized trials adopted from the prediction of adverse maternal outcomes in 320 
pre-eclampsia study.128 321 
 322 
Placental abruption: Participants unanimously agreed the definition developed as part of the 323 
Brighton Collaboration case definition study.20 324 
 325 
Postpartum hemorrhage: Participants discussed the challenges of defining postpartum 326 
hemorrhage when considering the contribution of the mode of delivery, estimating blood 327 
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loss, and differences in thresholds when further medical or surgical intervention to manage 328 
postpartum hemorrhage is deemed necessary. Participants agreed a common starting point 329 
is the recognition of heavy abnormal bleeding following childbirth. A specific volume 330 
threshold was considered unhelpful as there is marked inter-observer variability in estimating 331 
blood loss.129 Participants discussed the importance of demonstrating hypotension and/or 332 
the use of pharmacologic or surgical interventions to manage postpartum hemorrhage as 333 
important components of the consensus definition. 334 
 335 
Raised liver enzymes: Participants recognized that the reference ranges for liver 336 
transaminases vary both during the three trimesters of pregnancy and between different 337 
laboratories. Participants unanimously recommended the consensus definition should not 338 
state a specific threshold but that aspartate aminotransferase (AST) and alanine 339 
transaminase (ALT) should be elevated at least twice the upper limit of normal. 340 
 341 
Low platelets: Participants discussed the different thresholds defining thrombocytopenia, in 342 
pregnancy thrombocytopenia is defined as a platelet count of less than 150 x 109/L, 343 
however, counts below 100 x109/L are more typical in HELLP syndrome and in severe 344 
cases, the platelet count may fall below 30 x109/L.62,130 Participants agreed platelet counts 345 
below 100 x109/L should be used as the threshold for the consensus definition. 346 
 347 
Maternal admission to intensive care unit required: Participants unanimously agreed on a 348 
consensus definition. The definition highlights the importance of collecting and reporting the 349 
requirement for intensive care unit admission even if women are unable to be admitted to an 350 
intensive care unit because of logistics or availability of such services. The lack of capacity 351 
will be particularly relevant to research conducted in low- and middle-income countries.131 352 
 353 
Tracheal Intubation and mechanical ventilation not for purposes of operative delivery: 354 
Participants unanimously agreed a consensus definition. 355 




Fetal core outcomes 357 
Stillbirth: Participants reviewed the different definitions which incorporated different 358 
quantifiable parameters, including clinical estimates of gestational age, birth weight, and 359 
crown-heel height.32 Participants highlighted the World Health Organization’s definition for 360 
stillbirth is the most widely used.132 The inclusion of height and weight thresholds secures its 361 
feasibility in low- and middle-income countries.132 Consensus was reached to select the 362 
World Health Organization’s definition.14 363 
 364 
Gestational age at delivery: Participants considered gestational age at delivery as a well-365 
characterized outcome with an internationally accepted definition.21 There was unanimous 366 
agreement to adopt this definition. 367 
 368 
Birth weight: Participants agreed birth weight should be collected within 24 hours of birth.21 369 
Participants noted best practice recommendations regarding the measurement of birth 370 
weight should be adhered to in future pre-eclampsia research including weight assessed 371 
using a calibrated electronic scale with 10-gram resolution.21 Participants noted in low- and 372 
middle-income countries calibrated electronic scales may not be readily available, and the 373 
calibration and type of scale should be clearly reported. 374 
 375 
Small for gestational age: Participants discussed the importance of assessing small for 376 
gestational age using validated growth charts. A variety of different international, regional, 377 
and local growth charts are available.133 Participants unanimously agreed a 10th percentile 378 
threshold was appropriate to identify small for gestational age newborn infants and any 379 
validated international, regional, or local customized growth chart could be used. Participants 380 
agreed small for gestational age infants should be reported for all births, including stillbirths. 381 
 382 
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Neonatal core outcomes 383 
Neonatal mortality: Participants noted the consistent use of the World Health Organization 384 
definition for neonatal mortality, “deaths among live births during the first 28 completed days 385 
of life”, across definition development initiatives, international and national guidelines, 386 
Cochrane systematic reviews, and randomized controlled trials.14 Participants unanimously 387 
recommended this definition. 388 
 389 
Neonatal seizures: Participants noted World Health Organization guidelines described the 390 
most practical method of diagnosing neonatal seizures, based upon clinical recognition.134 391 
Neonatal seizures commonly present with focal clonic movements, however, they can 392 
present with more subtle signs which can be easily misinterpreted as either crying or cycling 393 
movements of the limbs.134 Electroencephalogram (EEG) monitoring can support the 394 
diagnosis. However, its availability in low- and middle-income countries is limited. 395 
Participants agreed a common starting point is the recognition of neonatal seizures. 396 
Separate definitions were agreed for high-income countries and low- and middle-income 397 
countries.  398 
  399 
Respiratory support: Participants agreed on a consensus definition which included 400 
continuous positive airway pressure, non-invasive positive pressure ventilation, or intubation 401 
and mechanical ventilation. Participants discussed the inclusion of supplemental oxygen; 402 
however concerns were expressed that this would represent an overly inclusive definition as 403 
supplemental oxygen is a commonly used non-specific intervention.135 404 
 405 
Admission to special care baby unit or neonatal intensive care unit required: Participants 406 
discussed the lack of consensus regarding the local, regional, or national criteria used to 407 
assess the need for admission to a special care baby unit or neonatal intensive care unit.136 408 
Consensus was reached to recommend a broad definition to recognize this variation in 409 
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admission criteria. The definition highlights the importance of collecting and reporting the 410 
requirement for admission to a special care baby unit or neonatal intensive care unit even if 411 
the neonate cannot be admitted. The lack of capacity will be particularly relevant to research 412 
conducted in low- and middle-income countries.137 413 
 414 
Comment 415 
When pre-eclampsia trials, systematic reviews, and clinical practice guidelines have 416 
previously reported individual outcomes, they have been defined in many different ways. In 417 
developing a core outcome set it is therefore important to rigorously define the outcomes 418 
chosen. Using robust consensus science methods, ten healthcare professionals and three 419 
researchers systematically considered 86 definitions previously developed by formal 420 
definition development initiatives, randomized controlled trials, Cochrane systematic reviews, 421 
and/or clinical practice guidelines. Consensus was reached for all 14 maternal, four fetal, 422 
and four neonatal core outcomes. When considering stroke, pulmonary edema, birth weight, 423 
and neonatal seizures, separate consensus definitions were developed for high-income 424 
countries and low- and middle-income countries because of the key role of imaging in the 425 
high-quality diagnosis of these conditions that may not be available in lower income settings. 426 
 427 
Interpretation 428 
Differences in the definition of individual outcomes can be accommodated in a meta‐429 
analysis. However, there are limits to what can be combined in a meaningful way due to 430 
heterogeneity, making it preferable to have core outcomes and definitions.6 Such 431 
standardized outcome definitions, should enable robust meta-analysis and facilitate more 432 
sophisticated secondary research, including individual patient data and network meta-433 
analysis. Effective evidence synthesis supports in turn the translation of research into clinical 434 
practice.139 435 
 436 
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Having established consensus definitions, primary and secondary researchers should use 437 
them, and guideline developers should build their clinical practice guidelines around them. 438 
Standardized consensus definitions are not meant to stifle the development and use of other 439 
appropriate definitions. For example, researchers undertaking research in Australia may 440 
wish to define stillbirth as occurring after 20 weeks of gestation in line with local 441 
Epidemiology and Surveillance Branch recommendations.5 Researchers wishing to collect 442 
data using other definitions in the context of their own randomized controlled trial would 443 
continue to be able to do so. However, selective reporting should be avoided  by presenting  444 
findings for both the consensus definition and any other definition used. Researchers would 445 
need to carefully consider how these data would be collected to fulfill different definitions. In 446 
the example of stillbirth, the common components of all definitions, including gestational age, 447 
birth weight, and crown-heel height, should be recorded separately and combined to fulfill 448 
the consensus definition (gestational age, birth weight, and crown-heel height) and the local 449 
definition (gestational age and birth weight). 450 
 451 
Standardized definitions should prevent misclassifications and reduce measurement error.140 452 
Such standardization ensures the consensus definitions can be applied symmetrically to the 453 
trial arms, avoiding bias in the measurements. Several consensus definitions, including 454 
abruption, postpartum hemorrhage, and neonatal seizures, require professional assessment. 455 
Any assessment should be determined by an observer with comprehensive training. 456 
Differential and biased misclassification of outcomes can occur in poorly designed 457 
randomized trials, for example, when outcome assessors are not blinded to the treatment 458 
allocation. Consider the diagnosis of postpartum hemorrhage: outcome assessors may 459 
perform laboratory investigations more regularly in participants allocated to the experimental 460 
treatment when compared to the control. Systematic evaluations of observer bias have 461 
demonstrated non-blinded outcome assessors consistently over diagnose clinical outcomes 462 
when compared with blinded outcome assessors.141 Several strategies exist to increase the 463 
likelihood standardized definitions are applied to accurately  classify clinical outcomes, 464 
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including standardized data collection tools, validation studies, and independent adjudication 465 
panels. This would increase the likelihood that core outcomes  are classified accurately and 466 
without variation .142 467 
 468 
A recent systematic review identified 33 core outcome sets relevant to pregnancy and 469 
childbirth currently under development.16 Each set will contain a unique collection of core 470 
outcomes. Ideally, core outcomes which overlap several core outcome sets should utilize a 471 
consistent definition. The International Collaboration to Harmonize Outcomes for Pre-472 
eclampsia (iHOPE) is establishing an inventory of outcome definitions relevant to pregnancy 473 
and childbirth research, which could facilitate the efficient development of definitions for 474 
different core outcome sets. The inventory catalogs available definitions within a regional, 475 
national, and international context and supporting validation studies. Maternal and newborn 476 
health is in a unique position to benefit from such an initiative as individual obstetric 477 
conditions, such as pre-eclampsia, gestational diabetes, and obstetric cholestasis, are likely 478 
to share common core outcomes, for example, maternal mortality, neonatal mortality, and 479 
neonatal seizures. 480 
 481 
The Core Outcomes in Women’s and Newborn Health (CROWN) initiative, supported by 482 
over 84 specialty journals, including the Cochrane Pregnancy and Childbirth Group, has 483 
resolved to implement the core outcome set for pre-eclampsia.143   Participating journals will 484 
require researchers to report the definition for individual core outcomes within published trial 485 
reports. When the consensus definition has not been used, the researchers will be asked to 486 
report this deficiency and its implications for their findings.143 With time researchers will 487 
anticipate this scrutiny, which should support the implementation of the core outcome set for 488 
pre-eclampsia. 489 
 490 
Strengths and weaknesses 491 
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This study has completed our overall objective of standardizing future pre-eclampsia 492 
research by identifying what outcomes to measure, when they should be measured, and 493 
how they should be measured. A comprehensive inventory of potential definitions was 494 
developed by a diverse range of researchers and healthcare professionals resulting in clear 495 
and objective definitions which could be used across settings.  496 
 497 
This study was not without limitations. Pre-eclampsia is a disease with a global impact, 498 
especially in low- and middle-income countries, where the societal burden of the disease is 499 
high.138 Participants in the consensus conference currently live in the United Kingdom, 500 
although six participants (46%) had lived, worked, or conducted research in a low- and 501 
middle-income country. This could have impacted on the generalisability of the consensus 502 
definitions prioritized but was a pragmatic choice in the light of limited resources which 503 
precluded inclusion of international participants. Use of the core outcome set in a variety of 504 
countries will ascertain the extent to which this is an issue and definitions may need further 505 
adjustment. 506 
 507 
The a priori definition of consensus used within this study was unanimous agreement. Once 508 
a consensus definition was formally agreed, participants had the opportunity to comment 509 
further. A contingency for participants who did not agree with a consensus definition was 510 
available but not used. The study could have been adjusted to undertake formal and 511 
anonymous voting to assess the level of agreement for individual consensus definitions. 512 
Individual participants could have rated their agreement with an individual consensus 513 
definition using a Likert scale anchored between strongly disagree and strongly agree. 514 
Further methodological research is required to develop an appropriate definition of 515 
consensus in exercises similar to ours. 516 
 517 
Conclusion 518 
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Ensuring core outcomes are consistently defined across future randomized controlled trials, 519 
systematic reviews, and clinical practice guidelines, will ensure evidence is more accessible 520 
and facilitate the translation of research into clinical practice. 521 
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